PEMF for Long
COVID Pain.

June 2026 · 11 min read · Post-Viral Protocol

The Long COVID Pain Problem

Long COVID — defined by the WHO as symptoms persisting or developing ≥4 weeks after acute SARS-CoV-2 infection, not explained by an alternative diagnosis — represents one of the largest newly created chronic pain populations in medical history. The Philippines recorded over 4 million confirmed COVID-19 cases by 2023, with true infection numbers estimated 5–10× higher due to underreporting during peak waves. Applying WHO's estimated 10–20% long COVID prevalence rate, the Philippines carries an estimated 400,000–800,000 individuals with long COVID — the majority of whom have never received targeted treatment.

Among long COVID symptom clusters, musculoskeletal complaints are among the most prevalent and disabling:

• Myalgia / widespread muscle pain: present in 31–44% of long COVID patients; often described as "body aches that don't go away" — a pattern distinct from typical DOMS or influenza myalgia
• Arthralgia (joint pain without arthritis): 28–35% prevalence; primarily affects large joints (knees, hips, shoulders) and small joints (hands, feet)
• Chronic fatigue: 58% of long COVID patients at 6 months; the dominant symptom in NICE's clinical definition of post-COVID syndrome
• Sleep disturbance: 44% prevalence; characterized by both insomnia and non-restorative sleep — worsens pain perception through altered central sensitization
• Neuropathic pain features: 20–26% report burning pain, allodynia, or hyperalgesia — consistent with post-viral peripheral nerve sensitization

The critical clinical insight for PEMF practitioners: each of these five symptom domains has an established PEMF evidence base from non-COVID populations — with RCT-level data demonstrating benefit in the underlying biological mechanisms that COVID-19 also disrupts.

The Biological Mechanisms: Why PEMF Addresses Long COVID Pain

Long COVID musculoskeletal symptoms are driven by three primary pathological processes: persistent low-grade systemic inflammation (elevated IL-6, TNF-α, and interferon-γ months after acute infection), mitochondrial dysfunction in muscle tissue (reduced ATP production, increased oxidative stress), and peripheral nerve sensitization (small-fiber neuropathy, dorsal root ganglion involvement). All three are documented PEMF targets:

1. Persistent Neuroinflammation and Neuropathic Pain

Post-COVID neuropathic pain shares the same biological substrate — sensitized nociceptive neurons, elevated CXCL12/CXCR4 signaling, and glial activation — as other forms of post-viral neuropathy. The 2026 meta-analysis of PEMF for neuropathic pain (PMC12943413, 13 RCTs, N=688) demonstrated a pooled SMD=-1.01 (95%CI -1.40 to -0.62, p<0.001) — a large effect size consistent across heterogeneous neuropathic pain etiologies. PEMF's mechanism in neuropathic pain operates through A2A receptor activation at dorsal horn synapses, reducing glutamate release and substance P-mediated central sensitization — the same pathway disrupted in post-COVID neurological symptoms.

2. Myalgia and Muscle Biochemical Disruption

Long COVID myalgia is associated with elevated circulating creatine kinase (CK), reduced mitochondrial complex I activity, and dysregulated calcium handling in type II muscle fibers. PEMF's effect on muscle cell biology is well-documented: the delayed onset muscle soreness RCT (PMC7477588, n=56) demonstrated 43% vs. 8% muscle pain reduction in the PEMF group (d=1.12, large effect), with 2.3× faster CK clearance. This CK clearance data is directly relevant to long COVID myalgia — where elevated CK in muscle tissue persists for months. The PEMF-mediated acceleration of CK clearance through improved microcirculation addresses the mechanism rather than just the symptom.

3. Fatigue and Mitochondrial Dysfunction

Chronic fatigue in long COVID is increasingly attributed to mitochondrial dysfunction — reduced ATP production in both skeletal muscle and neural tissue. PEMF at 25–75 Hz has been shown to increase mitochondrial electron transport chain activity and upregulate ATP synthesis in cellular models. Combined with the PEMF-mediated improvement in microcirculation (increased NO production, reduced perivenular edema), the mechanism for fatigue improvement is biologically grounded — though dedicated long COVID fatigue RCTs with PEMF are still in protocol stage as of 2026.

4. Anxiety and HPA-Axis Dysregulation

Post-COVID anxiety affects 26% of patients and is associated with HPA-axis hyperactivation — chronically elevated cortisol that feeds back into pain amplification and sleep disruption. The PEMF GAD RCT (PMC9748435, n=60) demonstrated HAMA anxiety score improvement of 40% vs. 14% in controls (p<0.001) with cortisol reduction of 28%. This cortisol normalization has downstream benefits for the entire long COVID symptom cluster — reducing central sensitization, normalizing sleep, and attenuating inflammatory signaling.

5. Sleep Dysfunction

Non-restorative sleep in long COVID amplifies all other symptoms through disrupted descending pain inhibition and elevated nocturnal IL-6. PEMF's sleep evidence (PMC7569862, n=52, insomnia RCT) shows PSQI improvement from 14.2 to 8.1 (scale: 0–21, lower=better), sleep onset -22 minutes, and wake after sleep onset (WASO) -31 minutes. Improved sleep architecture is not just a patient comfort measure — it is a pain management intervention in the context of central sensitization.

The Long COVID PEMF Evidence Matrix

The 3-Phase Long COVID PEMF Protocol

Long COVID musculoskeletal management requires a staged approach because the symptom cluster evolves over the treatment course. A single-frequency "pain" protocol misses the multi-system nature of the condition:

Coil Placement for Multi-Symptom Long COVID

• Dominant pain region first: if arthralgia > myalgia, start with the primary joint (knee/shoulder/hip). If myalgia > arthralgia, use a larger whole-back or limb coil for systemic muscle targeting.
• Lumbar-sacral placement: activates lumbosacral plexus — downstream effect on lower limb myalgia and addresses common long COVID lower back pain component
• Cervical placement (Phase 3): for neuropathic symptoms, allodynia, and sleep protocols — cervical vagal tone modulation is an emerging PEMF mechanism for autonomic nervous system normalization
• Session duration: 30–40 minutes. Start at 30 minutes in Phase 1 to assess energy tolerance (post-exertional malaise is common in long COVID and can be triggered by over-stimulation)
• Frequency: 2× per week for Phases 1–2; reduce to 1× per week for Phase 3 maintenance

Clinical Considerations: Long COVID-Specific Precautions

Long COVID patients require modified clinic protocols compared to standard musculoskeletal PEMF patients:

• Post-exertional malaise (PEM) screening: 44% of long COVID patients with fatigue report symptom worsening after physical or cognitive exertion. Screen for PEM before starting PEMF — if present, use the lowest comfortable intensity in Phase 1 sessions and monitor 24–48 hours after each session.
• Cardiovascular autonomic dysfunction: Long COVID is associated with postural orthostatic tachycardia syndrome (POTS) and heart rate variability abnormalities. Ensure patients sit or lie during treatment (no standing protocols). Monitor for dizziness after sessions.
• Medication interactions: Long COVID patients are frequently on anticoagulants (post-thrombotic sequelae), antidepressants (SSRIs/SNRIs for neurological symptoms), and immunomodulators. None of these are contraindications to PEMF, but document all current medications at intake.
• Outcome tracking: Use condition-specific tools alongside generic VAS — the PSQI for sleep, the HADS (Hospital Anxiety and Depression Scale), and a fatigue VAS. Long COVID improvement is multi-dimensional and single-metric tracking misses the treatment response.

The Philippine Long COVID Clinic Opportunity

Long COVID is a structurally underserved condition in the Philippine healthcare system. The DOH does not have a formal long COVID rehabilitation pathway as of 2026, and most long COVID patients in the Philippines are managed by primary care physicians with limited specialized pain management capacity. This creates a white-space opportunity for PEMF clinics willing to develop a targeted long COVID protocol.

The commercial model is compelling:

• Addressable population: 400,000–800,000 long COVID patients in the Philippines. Approximately 30–40% have pain as a primary complaint — 120,000–320,000 potential patients.
• High-value patient profile: Long COVID patients are typically working-age adults (25–55) who experienced moderate-to-severe acute COVID. They have above-average health literacy, strong motivation, and clear treatment goals (return to work, return to physical activity).
• Protocol revenue: A full 12-week long COVID PEMF course (24 sessions at ₱1,500–₱2,500/session) generates ₱36,000–₱60,000 per patient. The multi-symptom nature of the condition justifies the longer course compared to single-joint musculoskeletal conditions.
• Referral network: Long COVID patients are primarily managed by internal medicine, pulmonology, and infectious disease physicians — specialties with limited physical medicine capacity but strong motivation to offload complex rehabilitation cases. PEMF clinics can build systematic referral partnerships with these networks.
• Insurance positioning: As PhilHealth and private insurers develop long COVID benefit coverage, PEMF clinics with documented protocols and outcomes data are positioned to enter the reimbursement pathway. Early adoption of outcomes tracking creates a clinical evidence base for coverage negotiations.

From the 70+ Israeli clinics (population: 9M) now expanding to the Philippines, the long COVID patient management model has already been validated in a post-epidemic context. The Israeli experience positions PainFree Philippines to deploy a tested protocol into a larger, still-developing market.

Contraindications and Safety

PEMF's standard contraindications apply: active pacemaker or implanted electrical device, active pregnancy, active malignancy in the treatment field, and active epilepsy. For long COVID specifically, no additional contraindications have been identified. The non-invasive nature of PEMF — no ionizing radiation, no pharmacological load, no procedural risk — is a particular advantage for long COVID patients who are often already carrying significant pharmacological burden from acute management.

The primary safety consideration for long COVID is post-exertional malaise: use conservative intensity settings in first sessions and always leave 48 hours between sessions in Phase 1. If PEM is triggered after any session, reduce intensity by 25% in the next session and extend session intervals to every 5–7 days until tolerance improves.

Frequently Asked Questions

Is PEMF the right treatment for long COVID, or should patients see a specialist first?

PEMF is most appropriate as a component of multidisciplinary long COVID management — alongside primary care physician oversight, appropriate cardiac/pulmonary clearance if indicated, and psychological support for anxiety and sleep. For patients without red flags (chest pain, significant dyspnea, cognitive decline, new cardiac arrhythmia), PEMF for musculoskeletal pain and sleep can be started after a physician assessment confirms no acute cardiac or pulmonary sequelae.

How do I know if PEMF is working for my long COVID patient?

Track a baseline VAS for the primary pain complaint, PSQI for sleep, and a fatigue VAS at intake. Reassess at session 6 (approximately 3 weeks). A clinically meaningful response is ≥30% improvement in at least two of these three measures by session 8–10. If no response is observed by session 12, reconsider the protocol frequency and coil placement, or escalate to specialist review.

Can PEMF help with long COVID "brain fog"?

Cognitive symptoms (brain fog, memory difficulties, attention deficits) in long COVID are partially mediated by neuroinflammation, sleep disruption, and pain-related cognitive load. PEMF's effects on cortisol, sleep architecture, and pain will indirectly improve cognitive function. Direct neuromodulation of cognitive symptoms is outside the current PEMF evidence base — rTMS (repetitive transcranial magnetic stimulation) has more specific evidence for this indication.

Will this condition keep coming back?

Long COVID musculoskeletal symptoms follow a variable course: approximately 50–60% of patients show spontaneous improvement over 12 months, while 20–25% develop chronic symptoms. PEMF can accelerate recovery in the improving group and manage symptoms in the chronic group. Maintenance PEMF (1× per month after the initial course) is a reasonable ongoing protocol for patients with residual symptoms.